Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment

Vijayakumar Javalkar, MD, MCh; Okkes Kuybu, MD; Abdallah Amireh, MD; Roger E. Kelley, MD


South Med J. 2020;113(11):585-592. 

In This Article

Cervical Carotid Artery Dissection Study

In the CADISS (Cervical Artery Dissection in Stroke Study),[56] patients were randomized to antiplatelet therapy or heparin followed by warfarin for 3 months. This was then followed by therapy based upon the decision of the treating physician. The recurrent annual stroke rate was 2.4% for the intention-to-treat analysis and 2.5% for the efficacy analysis, with no difference between groups. There also was no difference observed in the recanalization rate on serial imaging.[57]

A meta-analysis of nonrandomized trials also did not find a significant difference in recurrent ipsilateral stroke with anticoagulation versus antiplatelet therapy for acute extracranial carotid artery dissections.[58]